During the years 2000-2004, the Company embarked on major restructuring and modernisation of its production facilities to make them compliant with US FDA/European regulations. The Company re-engineered its infrastructure and geared itself to meet the challenges facing the pharma industry.

The Company considers these financial years as periods of investment, while it is readying itself for the tougher global markets. The full benefits of globalisation and operating efficiencies have already started favourably impacting the growth of the Company.